Research published in European Neuropsychopharmacology (page 4)

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

European Neuropsychopharmacology May 20, 2016 Anna Rickli, Olivier D. Moning, Marius C. Hoener et al. 374 citations

The present study investigated interactions between the novel psychoactive tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at monoamine receptors and transporters compared with the classic hallucinogens lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), and mescaline. We investigated binding affinities at human monoamine receptors and determined...

DOI: 10.1016/j.euroneuro.2016.05.001

LSD modulates music-induced imagery via changes in parahippocampal connectivity.

European Neuropsychopharmacology April 12, 2016 Mendel Kaelen, Leor Roseman, Joshua Kahan et al. 143 citations

Psychedelic drugs such as lysergic acid diethylamide (LSD) were used extensively in psychiatry in the past and their therapeutic potential is beginning to be re-examined today. Psychedelic psychotherapy typically involves a patient lying with their eyes-closed during peak drug effects, while listening to music and being supervised by trained psychotherapists. In this context, music is...

DOI: 10.1016/j.euroneuro.2016.03.018 LSD Lysergic acid diethylamide Hallucinogens Psychedelics +18

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

European Neuropsychopharmacology March 26, 2016 Marta Valle, Ana Maqueda, Mireia Rabella et al. 175 citations

Ayahuasca is an Amazonian psychotropic plant tea typically obtained from two plants, Banisteriopsis caapi and Psychotria viridis. It contains the psychedelic 5-HT2A and sigma-1 agonist N,N-dimethyltryptamine (DMT) plus β-carboline alkaloids with monoamine-oxidase (MAO)-inhibiting properties. Although the psychoactive effects of ayahuasca have commonly been attributed solely to agonism at the...

DOI: 10.1016/j.euroneuro.2016.03.012 Ayahuasca Serotonin Ketanserin Hallucinogen +3

Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.

European Neuropsychopharmacology February 2016 Alexandre Seillier, Andrea Giuffrida

Previous studies have shown that social withdrawal in the phencyclidine (PCP) rat model of schizophrenia results from deficient endocannabinoid-induced activation of CB1 receptors. To understand the underlying cognitive mechanisms of the social deficit in PCP-treated rats, we examined the impact of pharmacological manipulation of the endocannabinoid system on sociability (i.e. social approach)...

DOI: 10.1016/j.euroneuro.2015.12.009 Full text Endocannabinoid Odor discrimination Phencyclidine Social cognition

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

European Neuropsychopharmacology January 22, 2016 Thomas Pokorny, Katrin H. Preller, Rainer Kraehenmann et al. 148 citations

The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT2A receptor activation. However, accumulating evidence suggests that 5-HT1A or an interaction...

DOI: 10.1016/j.euroneuro.2016.01.005 Psilocybin Buspirone Hallucinogen 5-ht1 receptor +5

Evaluation of brain SERT occupancy by resveratrol against MDMA-induced neurobiological and behavioral changes in rats: A 4-[¹⁸F]-ADAM/small-animal PET study.

European Neuropsychopharmacology January 2016 Jui-Hu Shih, Kuo-Hsing Ma, Chien-Fu F Chen et al.

The misuse of 3,4-methylenedioxymethamphetamine (MDMA) has drawn a growing concern worldwide for its psychophysiological impacts on humans. MDMA abusers are often accompanied by long-term serotonergic neurotoxicity, which is associated with reduced density of cerebral serotonin transporters (SERT) and depressive disorders. Resveratrol (RSV) is a natural polyphenolic phytoalexin that has been...

DOI: 10.1016/j.euroneuro.2015.11.001 Full text MDMA 4-18f-adam Occupancy Resveratrol +2

Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats.

European Neuropsychopharmacology December 2015 Erica Zamberletti, Marina Gabaglio, Pamela Prini et al.

Over 180 million people consume cannabis globally. Cannabis use peaks during adolescence with a trend for continued consumption by adults. Notably, several studies have shown that long-term and heavy cannabis use during adolescence can impair brain maturation and predispose to neurodevelopmental disorders, although the neurobiological mechanisms underlying this association remain largely...

DOI: 10.1016/j.euroneuro.2015.09.021 Full text THC Adolescence Cognition Neuroinflammation +2

Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users.

European Neuropsychopharmacology November 2015 Mikael A Kowal, Henk Van Steenbergen, Lorenza S. Colzato et al.

Cannabis has been suggested to impair the capacity to recognize discrepancies between expected and executed actions. However, there is a lack of conclusive evidence regarding the acute impact of cannabis on the neural correlates of error monitoring. In order to contribute to the available knowledge, we used a randomized, double-blind, between-groups design to investigate the impact of...

DOI: 10.1016/j.euroneuro.2015.08.001 Full text Cannabis THC Error monitoring Error positivity +1

Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.

European Neuropsychopharmacology October 2015 Magí Farré, Angels Tomillero, Clara Pérez‐mañá et al.

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a popular psychostimulant, frequently associated with multiple administrations over a short period of time. Repeated administration of MDMA in experimental settings induces tolerance and metabolic inhibition. The aim is to determine the acute pharmacological effects and pharmacokinetics resulting from two consecutive 100mg doses of MDMA...

DOI: 10.1016/j.euroneuro.2015.05.007 Full text Ecstasy MDMA Cyp2d6 Pharmacokinetics +2

Role of the nitric oxide donor sodium nitroprusside in the antidepressant effect of ketamine in mice.

European Neuropsychopharmacology October 1, 2015 Miriam A Vogt, Anne S Vogel, Natascha Pfeiffer et al.

Ketamine may represent an efficient alternative antidepressant with rapid therapeutic onset; however, the clinical use of ketamine is hampered by psychosis-like side-effects. Recent studies suggest that the nitric oxide (NO) donor sodium nitroprusside (SNP) prevents psychosis-like abnormalities triggered by ketamine or another NMDA receptor (NMDAR) antagonist, phencyclidine (PCP) in rats. SNP...

DOI: 10.1016/j.euroneuro.2015.06.012 Full text Depression Ketamine Nmda receptor Nitric oxide +1

Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption.

European Neuropsychopharmacology June 2015 Cristina A J Stern, Lucas Gazarini, Ana C Vanvossen et al.

Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the major constituents of the Cannabis sativa plant, which is frequently consumed by subjects exposed to life-threatening situations to relief their symptomatology. It is still unknown, however, whether THC could also affect the maintenance of an aversive memory formed at that time when taken separately and/or in conjunction with CBD....

DOI: 10.1016/j.euroneuro.2015.02.001 Full text Cannabidiol Cb1 receptor Fear memory Medial prefrontal cortex +2

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

European Neuropsychopharmacology March 2015 Chandni Hindocha, Tom P. Freeman, Gráinne Schäfer et al.

Acute administration of the primary psychoactive constituent of cannabis, Δ-9-tetrahydrocannabinol (THC), impairs human facial affect recognition, implicating the endocannabinoid system in emotional processing. Another main constituent of cannabis, cannabidiol (CBD), has seemingly opposite functional effects on the brain. This study aimed to determine the effects of THC and CBD, both alone and...

DOI: 10.1016/j.euroneuro.2014.11.014 Full text Cannabidiol CBD Emotional processing Endocannabinoid system Schizotypy +1

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans

European Neuropsychopharmacology January 16, 2015 José Carlos Bouso, Fernanda Palhano-Fontes, Antoni Rodrı́guez-fornells et al. 221 citations

Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception, emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that...

DOI: 10.1016/j.euroneuro.2015.01.008 Default mode network Posterior cingulate Hallucinogen Dissociative +3

Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis.

European Neuropsychopharmacology January 2015 Sagnik Bhattacharyya, Zerrin Atakan, Rocío Martín‐Santos et al.

Cannabis use can induce acute psychotic symptoms and increase the risk of schizophrenia. Impairments in inhibitory control and processing are known to occur both under the influence of cannabis and in schizophrenia. Whether cannabis-induced impairment in inhibitory processing is related to the acute induction of psychotic symptoms under its influence is unclear. We investigated the effects of...

DOI: 10.1016/j.euroneuro.2014.11.018 Full text Cannabis THC Functional MRI Inferior frontal gyrus +2

Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships

European Neuropsychopharmacology December 4, 2014 Yasmin Schmid, Cédric M. Hysek, Katrin H. Preller et al. 39 citations

Methylphenidate mainly enhances dopamine neurotransmission whereas 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") mainly enhances serotonin neurotransmission. However, both drugs also induce a weaker increase of cerebral noradrenaline exerting sympathomimetic properties. Dopaminergic psychostimulants are reported to increase sexual drive, while serotonergic drugs typically impair sexual...

DOI: 10.1016/j.euroneuro.2014.11.020 MDMA Methylphenidate Clinical psychology

Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice.

European Neuropsychopharmacology November 2014 Konstantin Kuteykin-Teplyakov, Rafaël Maldonado

Social behavior plays a fundamental role in life of many animal species, allowing the interaction between individuals and sharing of experiences, needs, and goals across them. In humans, some neuropsychiatric diseases, including anxiety, posttraumatic stress disorder and autism spectrum disorders, are often characterized by impaired sociability. Here we report that...

DOI: 10.1016/j.euroneuro.2014.08.007 Full text 4-methylenedioxyamphetamine 5-ht1a receptor N-methyl-3 Oxytocin +2

Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases.

European Neuropsychopharmacology August 2014 Ruud P. W. Litjens, Tibor M Brunt, Gerard-Jan Alderliefste et al.

Hallucinogen persisting perception disorder (HPPD) is a drug-induced condition associated with inaccurate visual representations. Since the underlying mechanism(s) are largely unknown, this review aims to uncover aspects underlying its etiology. Available evidence on HPPD and drug-related altered visual processing was reviewed and the majority of HPPD cases were attributed to drugs with...

DOI: 10.1016/j.euroneuro.2014.05.008 Full text 5-ht2a receptor Ecstasy LSD MDMA +2

Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats.

European Neuropsychopharmacology July 2014 Serena Stopponi, Laura Soverchia, Massimo Ubaldi et al.

Cannabis derivatives are among the most widely used illicit substances among young people. The addictive potential of delta-9-tetrahydrocannabinol (THC), the major active ingredient of cannabis is well documented in scientific literature. However, the consequence of THC exposure during adolescence on occurrence of addiction for other drugs of abuse later in life is still controversial. To...

DOI: 10.1016/j.euroneuro.2013.12.012 Full text Addiction Anxiety THC Adolescence +1

Increased cortisol levels in hair of recent Ecstasy/MDMA users.

European Neuropsychopharmacology March 1, 2014 Andrew C. Parrott, H. Sands, Lewis Jones et al. 35 citations

Previous research has revealed an acute 8-fold increase in salivary cortisol following self-administrated Ecstasy/MDMA in dance clubbers. It is currently not known to what extent repeated usage impacts upon activity of the hypothalamic-pituitary-adrenal axis over a more prolonged period of time. This study investigated the integrated cortisol levels in 3-month hair samples from recent...

DOI: 10.1016/j.euroneuro.2013.11.006 Full text

Psilocybin – Summary of knowledge and new perspectives

European Neuropsychopharmacology December 17, 2013 Filip Tylš, Tomáš Páleníček, Jiřı́ Horáček 267 citations

Psilocybin, a psychoactive alkaloid contained in hallucinogenic mushrooms, is nowadays given a lot of attention in the scientific community as a research tool for modeling psychosis as well as due to its potential therapeutic effects. However, it is also a very popular and frequently abused natural hallucinogen. This review summarizes all the past and recent knowledge on psilocybin. It briefly...

DOI: 10.1016/j.euroneuro.2013.12.006 Psilocybin Hallucinogen Action physics Pharmacology

Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro.

European Neuropsychopharmacology September 2013 Ran Barzilay, Javier Ganz, Ofer Sadan et al.

Mesenchymal stem cells (MSCs) are an attractive cell source for regenerative medicine strategies in brain diseases. Experimental studies have shown that repeated administration of phencyclidine (PCP) leads to schizophrenia-like behavioral changes in mice. The aim of the present study was to explore the effectiveness of MSC transplantation into the hippocampus in attenuating PCP-induced social...

DOI: 10.1016/j.euroneuro.2012.10.002 Full text Animal model Phencyclidine Regenerative medicine Schizophrenia +2

Acutely applied MDMA enhances long-term potentiation in rat hippocampus involving D1/D5 and 5-HT2 receptors through a polysynaptic mechanism.

European Neuropsychopharmacology August 2012 Carlos Rozas, Sebastian Loyola, G Ugarte et al.

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a drug of abuse that induces learning and memory deficit. However, there are no experimental data that correlate the behavioral evidence with models of synaptic plasticity such as long-term potentiation (LTP) or long-term depression (LTD). Using field potential recordings in rat hippocampal slices of young rats, we found that acute...

DOI: 10.1016/j.euroneuro.2011.11.010 Full text

Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life.

European Neuropsychopharmacology May 2012 Teresa Marie Du Bois, Kelly Anne Newell, Xu-Feng Huang

Schizophrenia is a complex and devastating mental disorder of unknown etiology. Hypofunction of N-methyl-D-aspartate (NMDA) receptors are implicated in the disorder, since phencyclidine (PCP) and other NMDA receptor antagonists mimic schizophrenia-like symptoms in humans and animals so well. Moreover, genetic linkage and post mortem studies strongly suggest a role for altered neuregulin 1...

DOI: 10.1016/j.euroneuro.2011.09.002 Full text

Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo.

European Neuropsychopharmacology April 2012 Matthew J Robson, Meenal Elliott, Michael J Seminerio et al.

Ketamine is an NMDA antagonist and dissociative anesthetic that has been shown to display rapid acting and prolonged antidepressant activity in small-scale human clinical trials. Ketamine also binds to σ receptors, which are believed to be protein targets for a potential new class of antidepressant medications. The purpose of this study was to determine the involvement of σ receptors in the...

DOI: 10.1016/j.euroneuro.2011.08.002 Full text

Prefrontal NMDA receptor antagonism reduces impairments in pre-attentive information processing.

European Neuropsychopharmacology March 2011 Daniel Klamer, Lennart Svensson, Kim Fejgin et al.

A well established theory proposes that glutamate signalling via the NMDA receptor is compromised in patients with schizophrenia. Deficits related to NMDA receptor signalling can be observed in several brain regions including the prefrontal cortex (PFC), an area extensively linked to the cognitive dysfunction in this disease and notably affected by NMDA receptor antagonists such as...

DOI: 10.1016/j.euroneuro.2010.10.010 Full text

Papers